Tatva Chintan Pharma gains after Q2 PAT more than doubles to Rs 21 cr
Mumbai, Oct. 21 -- Net sales jumped 75.94% year-on-year (YoY) to Rs 217.32 crore in the quarter ended 30 September 2026.
Profit before tax (PBT) soared 111.70% YoY to Rs 28.94 crore in Q2 FY27.
EBITDA surged 83% YoY to approximately Rs 40.7 crore in Q2 FY27, compared with Rs 22.2 crore in Q2 FY26. EBITDA margin improved to 19% from 18% in the corresponding quarter last year.
In terms of revenue contribution, Structure Directing Agents (SDA) accounted for 45% of total revenue, followed by Pharma & Agrochemical Intermediates (PASC) at 30%, Phase Transfer Catalysts (PTC) at 21%, Electrolyte Salts (ESS) at 3% and other products at 1%.
For the first half of FY27, the company reported a 125.93% rise in consolidated net profit to Rs 37.4 cro...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.